LM215 - Adverse Events in Tinnitus Management: Understanding Fluctuations and Reporting Biases

Abstract:
Managing tinnitus remains a complex challenge, especially regarding symptoms that worsen or fluctuate. This presentation explores adverse events (AEs) related to tinnitus, focusing on fluctuations and the need for clinical guidance. A literature review of systematic reviews and clinical trial registries revealed significant underreporting of AEs for many tinnitus management strategies, particularly with hearing aids and sound generators. Tinnitus worsening was the most frequently reported AE, with similar occurrence rates between interventions and control conditions. These findings highlight the importance of a clinical framework to manage tinnitus-related AEs, emphasizing baseline assessments, patient education, and systematic treatment adjustments.

Summary:
Rationale
Managing tinnitus remains challenging for both clinicians and patients, particularly in dealing with symptoms that worsen, fluctuate, or persist over time. This presentation delves into AEs related to tinnitus, focusing on the unpredictability of tinnitus fluctuations and emphasizing the need for clinical guidance to address these challenges effectively.

Design
A comprehensive review of clinical literature was conducted, focusing on systematic reviews and meta-analyses retrieved from the PubMed database. The review assessed the occurrence of "increased tinnitus" as an AE associated with tinnitus management strategies, including hearing aids, cochlear implants, sound generators, and psychotherapeutic approaches. Additionally, an analysis of clinical trial registries was performed to identify commonly reported AEs in trials involving tinnitus patients, with a focus on fluctuations and their occurrence rates (95 percent CI) across active interventions and control conditions.

Results
The literature review highlighted significant underreporting of AEs for most tinnitus management strategies, particularly with hearing aids and sound generators. While studies suggest that worsened tinnitus occurs at low rates (2-10 percent), many fail to thoroughly assess or document AEs, indicating a clear reporting bias. In contrast, cochlear implants consistently report AEs, with up to 25 percent of patients experiencing increased tinnitus post-implantation. Reports on AEs related to cognitive behavioral therapy (CBT) and psychotherapy are similarly scarce.

The clinical trial registry review provided a more detailed view of AEs. Of 40 trials included in the analysis, 16 reported AEs, with most trials on behavioral interventions failing to report AEs (89 percent). Notably, nearly two-thirds of trials on devices also did not report AEs (61 percent), whereas drug interventions had more consistent reporting (only 11 percent not reporting). No clinical trials investigating hearing aids as an intervention for tinnitus were identified.

Tinnitus worsening was the most frequently reported AE across all trials, which included drug interventions, neuromodulation, and masking devices. Similar confidence intervals for tinnitus fluctuations were observed between active interventions (1.8-12.2 percent) and control conditions (2.5-12.4 percent). Other frequently reported AEs, including headache, vertigo, ear discomfort, and dizziness, occurred at lower rates than tinnitus fluctuations but still showed similar patterns between treatment and control conditions.

Conclusion
The similarity in AE occurrence rates between treatment and control conditions suggests that tinnitus fluctuations may be more indicative of the natural course of the condition itself rather than a direct consequence of interventions. This, combined with the lack of AE reporting in 24 trials, underscores a significant reporting bias, particularly for behavioral interventions like CBT and hearing aids.

There is an urgent need for an established clinical framework to manage AEs in tinnitus patients, especially given the high incidence of tinnitus fluctuations. A proposed clinical process includes thorough baseline assessments, patient education, systematic evaluation of potential causes (e.g., timing, dosage, and external factors), and tailored adjustments to the treatment plan, followed by long-term patient monitoring.

Brief Summary of Clinical Takeaways:
AEs in tinnitus treatments, such as with hearing aids and CBT, are underreported, impacting safety assessments. Clinicians should address this bias. Common AEs should guide patient care decisions. Tinnitus fluctuations may reflect natural condition progression, not treatment. A structured approach is key to managing fluctuations.